Catalytic asymmetric total synthesis of diazabicyclooctane β-lactamase inhibitors avibactam and relebactam

Zhi Yang,Yu Chen,Xiangling Cen,Pei Tang,Lin-Xi Wan,Fen-Er Chen
DOI: https://doi.org/10.1039/d2cc04006a
IF: 4.9
2022-08-27
Chemical Communications
Abstract:Catalytic asymmetric total synthesis of avibactam and relebactam, two marketed diazabicyclooctane (DBO) β-lactamase inhibitors (BLIs), has been accomplished. An important feature of this study is the creation of a stereogenic center by using Rh-catalysed asymmetric hydrogenation, affording the crucial α-amino acid ester derivative with high-level enantiocontrol (99% ee). Furthermore, the adoption of flow technologies for the assembly of a majority of intermediates significantly achieves faster preparation and greater synthetic efficiency than corresponding batch procedures.
chemistry, multidisciplinary
What problem does this paper attempt to address?